U.S. FDA Approves AOP Health’s RapiblykTM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

Contributed by: Business Wire

Logo

Images

Portrait of Dr. Martin Steinhart, CEO AOP Health (Photo: AOP Health/Studio Koekart)

Business Wire embedded0

Tags

Health

FDA

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

supraventricular tachycardia

More Like This

Martin Steinhart, CEO, AOP Health; Copyright: AOP Health/Studio Koekart

AOP Health Receives Market Authorization for Landiolol in Canada

PR Newswire associated0

XYRA Announces Issuance of US Patent to Reduce the Risk of Heart Failure or Strokes by Reducing the Number and Duration of Atrial Fibrillations

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

PR Newswire associated0

XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation

Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

PR Newswire associated0

XYRA Announces the Issuance of a Fifth New US Patent in a Series of Patents Which Protect the Use of Budiodarone in the Management of Atrial Fibrillation till after 2040

Group photo management AOP Health and RHEACELL, from left to right: Dr. Christoph Ganss, Dr. Andreas Kluth, RHEACELL Dr. Rudolph Widmann, Dr. Günther Krumpl, Dr. Martin Steinhart, Bernhard Nachbaur, LL.M., AOP Health

RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the “Butterfly Children’s Disease” and Chronic Venous Wounds

Professor Heinz Gisslinger, MedUni Vienna/Austria (Fotocredit: IntMedCom)

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera to Be Presented at the American Society of Hematology (ASH) 65th Annual Meeting